Europe Pharmacokinetics Services Market Forecast to 2031

At 7.2% CAGR, Europe Pharmacokinetics Services Market is Projected to be Worth US$ 387.38 Million by 2031, says Business Market Insights

According to Business Market Insights’ research, the Europe pharmacokinetics services market was valued at US$ 222.16 million in 2023 and is expected to reach US$ 387.38 million by 2031, registering a CAGR of 7.2% from 2023 to 2031. Expanding range of application of pharmacokinetic studies and outsourcing of pharmacokinetics services to CROs are among the critical factors attributed to drive the Europe pharmacokinetics services market growth.

Pharmacokinetic studies are being employed to determine several parameters such as human-equivalent doses (HED) level, no-observed effect level (NOEL), and pharmacokinetic/pharmacodynamic testing. The main focus of any pre-clinical program conducted is to support the analysis of a safe and effective dose range for testing in pharmacokinetic studies. Several toxicology studies conducted data on the NOEL, i.e., the highest dose that does not produce adverse effects. This dose level is further converted to a HED level on a comparative body-surface area basis if there is lack of clinical pharmacokinetic data. Understanding the pharmacokinetic profile of a potential drug candidate plays an important role in the drug discovery program. Regulatory authorities play a major role propelling the implementation of pharmacokinetic studies. These studies are also instrumental in optimizing pharmaceutical care services provided to patients admitted in hospitals. The PK model is often applied to determine exposure to drugs, concentrations of drugs to analyze optimal dosage, and analyze the disposition of drugs in the human body. Healthcare providers implement the principles of PK to design monitor drug concentrations, doses of some drugs, maximize the intended therapeutic outcomes and minimize toxicities.

On the contrary, limited reach of pharmacokinetics service providers in emerging countries hampers the growth of Europe pharmacokinetics services market.

Based on drug type, the Europe pharmacokinetics services market is segmented small molecule, large molecule, and vaccines. The small molecule segment held 50.6% market share in 2023, amassing US$ 112.37 million. It is projected to garner US$ 202.28 million by 2031 to register 7.6% CAGR during 2023-2031.

In terms of service type, the Europe pharmacokinetics services market is categorized into pre-clinical ADME and human studies, PK/PD analysis and reporting, dosing simulations, risk analysis, and others. The pre-clinical ADME and human studies segment held 35.4% share of Europe pharmacokinetics services market in 2023, amassing US$ 78.54 million. It is anticipated to garner US$ 150.73 million by 2031 to expand at 8.5% CAGR during 2023-2031.

By therapeutic application, the Europe pharmacokinetics services market is segmented into oncology, infectious diseases, neurological disorders, autoimmune diseases, gynecological disorders, cardiovascular diseases, respiratory disorders, and others. The oncology segment held 22.3% market share in 2023, amassing US$ 49.51 million. It is projected to garner US$ 95.67 million by 2031 to register 8.6% CAGR during 2023-2031.

By end user, the Europe pharmacokinetics services market is segmented into pharmaceutical and biotechnology companies, contract research organization, and others. The contract research organization segment held 43.3% market share in 2023, amassing US$ 96.18 million. It is projected to garner US$ 177.18 million by 2031 to register 7.9% CAGR during 2023-2031.

By country, the Europe pharmacokinetics services market is segmented into Germany, France, the UK, Italy, Spain, and the Rest of Europe. Our regional analysis states that France captured 22.2% share of Europe pharmacokinetics services market in 2023. It was assessed at US$ 49.21 million in 2023 and is likely to hit US$ 95.06 million by 2031, registering a CAGR of 8.6% during 2023-2031.

Key players operating in the Europe pharmacokinetics services market are Charles River Laboratories International Inc; Eurofins Scientific SE; Evotec SE; Certara Inc.; Parexel International Corp; Thermo Fisher Scientific Inc.; Allucent; PACIFIC BIOLABS; and SGS SA; among others.

o Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the Europe pharmacokinetics services market.
o Highlights key business priorities in order to assist companies to realign their business strategies.
o The key findings and recommendations highlight crucial progressive industry trends in the Europe pharmacokinetics services market, thereby allowing players across the value chain to develop effective long-term strategies.
o Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
o Scrutinize in-depth Europe market trends and outlook coupled with the factors driving the Europe pharmacokinetics services market, as well as those hindering it.
o Enhance the decision-making process by understanding the strategies that underpin commercial interest with respect to client products, segmentation, pricing, and distribution.

TABLE OF CONTENTS

1. Introduction
1.1 The Research Team Research Report Guidance
1.2 Market Segmentation
2. Executive Summary
2.1 Key Insights
3. Research Methodology
3.1 Coverage
3.2 Secondary Research
3.3 Primary Research
4. Europe Pharmacokinetics Services Market – Key Market Dynamics
4.1 Market Drivers
4.1.1 Rising Prevalence of Chronic and Infectious Diseases
4.1.2 Expanding Range of Application of Pharmacokinetic Studies
4.1.3 Outsourcing of Pharmacokinetics Services to CROs
4.2 Market Restraints
4.2.1 Limited Reach of Pharmacokinetics Service Providers in Emerging Countries
4.3 Market Opportunities
4.3.1 Increasing Adoption of In-Vivo and In-Vitro Models for Understanding Variability in Pharmacokinetics
4.4 Future Trend
4.4.1 Increasing Adoption of Big Data Analytics in Pharmacokinetics Services
4.5 Impact of Drivers and Restraints:
5. Pharmacokinetics Services Market – Europe Analysis
5.1 Europe Pharmacokinetics Services Market Revenue (US$ Million), 2021-2031
6. Europe Pharmacokinetics Services Market Analysis – by Drug Type
6.1 Overview
6.2 Small Molecule
6.2.1 Overview
6.2.2 Small Molecule: Europe Pharmacokinetics Services Market – Revenue and Forecast to 2031 (US$ Million)
6.3 Large Molecule
6.3.1 Overview
6.3.2 Large Molecule: Europe Pharmacokinetics Services Market – Revenue and Forecast to 2031 (US$ Million)
6.4 Vaccines
6.4.1 Overview
6.4.2 Vaccines: Europe Pharmacokinetics Services Market – Revenue and Forecast to 2031 (US$ Million)
7. Europe Pharmacokinetics Services Market Analysis – by Service Type
7.1 Overview
7.2 Pre-Clinical ADME and Human Studies
7.2.1 Overview
7.2.2 Pre-Clinical ADME and Human Studies: Europe Pharmacokinetics Services Market – Revenue and Forecast to 2031 (US$ Million)
7.3 PK/PD Analysis and Reporting
7.3.1 Overview
7.3.2 PK/PD Analysis and Reporting: Europe Pharmacokinetics Services Market – Revenue and Forecast to 2031 (US$ Million)
7.4 Dosing Simulations
7.4.1 Overview
7.4.2 Dosing Simulations: Europe Pharmacokinetics Services Market – Revenue and Forecast to 2031 (US$ Million)
7.5 Risk Analysis
7.5.1 Overview
7.5.2 Risk Analysis: Europe Pharmacokinetics Services Market – Revenue and Forecast to 2031 (US$ Million)
7.6 Others
7.6.1 Overview
7.6.2 Others: Europe Pharmacokinetics Services Market – Revenue and Forecast to 2031 (US$ Million)
8. Europe Pharmacokinetics Services Market Analysis – by Therapeutic Application
8.1 Oncology
8.1.1 Overview
8.1.2 Oncology: Europe Pharmacokinetics Services Market – Revenue and Forecast to 2031 (US$ Million)
8.2 Infectious Diseases
8.2.1 Overview
8.2.2 Infectious Diseases: Europe Pharmacokinetics Services Market – Revenue and Forecast to 2031 (US$ Million)
8.3 Neurological Disorders
8.3.1 Overview
8.3.2 Neurological Disorders: Europe Pharmacokinetics Services Market – Revenue and Forecast to 2031 (US$ Million)
8.4 Autoimmune Diseases
8.4.1 Overview
8.4.2 Autoimmune Diseases: Europe Pharmacokinetics Services Market – Revenue and Forecast to 2031 (US$ Million)
8.5 Gynecological Disorders
8.5.1 Overview
8.5.2 Gynecological Disorders: Europe Pharmacokinetics Services Market – Revenue and Forecast to 2031 (US$ Million)
8.6 Cardiovascular Diseases
8.6.1 Overview
8.6.2 Cardiovascular Diseases: Europe Pharmacokinetics Services Market – Revenue and Forecast to 2031 (US$ Million)
8.7 Respiratory Disorders
8.7.1 Overview
8.7.2 Respiratory Disorders: Europe Pharmacokinetics Services Market – Revenue and Forecast to 2031 (US$ Million)
8.8 Others
8.8.1 Overview
8.8.2 Others: Europe Pharmacokinetics Services Market – Revenue and Forecast to 2031 (US$ Million)
9. Europe Pharmacokinetics Services Market Analysis – by End User
9.1 Pharmaceutical and Biotechnology Companies
9.1.1 Overview
9.1.2 Pharmaceutical and Biotechnology Companies: Europe Pharmacokinetics Services Market – Revenue and Forecast to 2031 (US$ Million)
9.2 Contract Research Organization
9.2.1 Overview
9.2.2 Contract Research Organization: Europe Pharmacokinetics Services Market – Revenue and Forecast to 2031 (US$ Million)
9.3 Others
9.3.1 Overview
9.3.2 Others: Europe Pharmacokinetics Services Market – Revenue and Forecast to 2031 (US$ Million)
10. Europe Pharmacokinetics Services Market – Country Analysis
10.1 Europe
10.1.1 Europe Pharmacokinetics Services Market Breakdown by Countries, 2023 and 2031 (%)
10.1.1.1 Germany: Europe Pharmacokinetics Services Market – Revenue and Forecast to 2031 (US$ Million)
10.1.1.1.1 Overview
10.1.1.1.2 Germany: Europe Pharmacokinetics Services Market – Revenue and Forecast to 2031 (US$ Million)
10.1.1.1.3 Germany: Europe Pharmacokinetics Services Market Breakdown, by Drug Type
10.1.1.1.4 Germany: Europe Pharmacokinetics Services Market Breakdown, by Service Type
10.1.1.1.5 Germany: Europe Pharmacokinetics Services Market Breakdown, by Therapeutic Application
10.1.1.1.6 Germany: Europe Pharmacokinetics Services Market Breakdown, by End User
10.1.1.2 France: Europe Pharmacokinetics Services Market – Revenue and Forecast to 2031 (US$ Million)
10.1.1.2.1 Overview
10.1.1.2.2 France: Europe Pharmacokinetics Services Market – Revenue and Forecast to 2031 (US$ Million)
10.1.1.2.3 France: Europe Pharmacokinetics Services Market Breakdown, by Drug Type
10.1.1.2.4 France: Europe Pharmacokinetics Services Market Breakdown, by Service Type
10.1.1.2.5 France: Europe Pharmacokinetics Services Market Breakdown, by Therapeutic Application
10.1.1.2.6 France: Europe Pharmacokinetics Services Market Breakdown, by End User
10.1.1.3 United Kingdom: Europe Pharmacokinetics Services Market – Revenue and Forecast to 2031 (US$ Million)
10.1.1.3.1 Overview
10.1.1.3.2 United Kingdom: Europe Pharmacokinetics Services Market – Revenue and Forecast to 2031 (US$ Million)
10.1.1.3.3 United Kingdom: Europe Pharmacokinetics Services Market Breakdown, by Drug Type
10.1.1.3.4 United Kingdom: Europe Pharmacokinetics Services Market Breakdown, by Service Type
10.1.1.3.5 United Kingdom: Europe Pharmacokinetics Services Market Breakdown, by Therapeutic Application
10.1.1.3.6 United Kingdom: Europe Pharmacokinetics Services Market Breakdown, by End User
10.1.1.4 Italy: Europe Pharmacokinetics Services Market – Revenue and Forecast to 2031 (US$ Million)
10.1.1.4.1 Overview
10.1.1.4.2 Italy: Europe Pharmacokinetics Services Market – Revenue and Forecast to 2031 (US$ Million)
10.1.1.4.3 Italy: Europe Pharmacokinetics Services Market Breakdown, by Drug Type
10.1.1.4.4 Italy: Europe Pharmacokinetics Services Market Breakdown, by Service Type
10.1.1.4.5 Italy: Europe Pharmacokinetics Services Market Breakdown, by Therapeutic Application
10.1.1.4.6 Italy: Europe Pharmacokinetics Services Market Breakdown, by End User
10.1.1.5 Spain: Europe Pharmacokinetics Services Market – Revenue and Forecast to 2031 (US$ Million)
10.1.1.5.1 Overview
10.1.1.5.2 Spain: Europe Pharmacokinetics Services Market – Revenue and Forecast to 2031 (US$ Million)
10.1.1.5.3 Spain: Europe Pharmacokinetics Services Market Breakdown, by Drug Type
10.1.1.5.4 Spain: Europe Pharmacokinetics Services Market Breakdown, by Service Type
10.1.1.5.5 Spain: Europe Pharmacokinetics Services Market Breakdown, by Therapeutic Application
10.1.1.5.6 Spain: Europe Pharmacokinetics Services Market Breakdown, by End User
10.1.1.6 Rest of Europe Pharmacokinetics Services Market – Revenue and Forecast to 2031 (US$ Million)
10.1.1.6.1 Overview
10.1.1.6.2 Rest of Europe Pharmacokinetics Services Market – Revenue and Forecast to 2031 (US$ Million)
10.1.1.6.3 Rest of Europe Pharmacokinetics Services Market Breakdown, by Drug Type
10.1.1.6.4 Rest of Europe Pharmacokinetics Services Market Breakdown, by Service Type
10.1.1.6.5 Rest of Europe Pharmacokinetics Services Market Breakdown, by Therapeutic Application
10.1.1.6.6 Rest of Europe Pharmacokinetics Services Market Breakdown, by End User
11. Company Profile
11.1 Charles River Laboratories International Inc
11.1.1 Key Facts
11.1.2 Business Description
11.1.3 Products and Services
11.1.4 Financial Overview
11.1.5 SWOT Analysis
11.1.6 Key Developments
11.2 Eurofins Scientific SE
11.2.1 Key Facts
11.2.2 Business Description
11.2.3 Products and Services
11.2.4 Financial Overview
11.2.5 SWOT Analysis
11.2.6 Key Developments
11.3 Evotec SE
11.3.1 Key Facts
11.3.2 Business Description
11.3.3 Products and Services
11.3.4 Financial Overview
11.3.5 SWOT Analysis
11.3.6 Key Developments
11.4 Certara Inc.
11.4.1 Key Facts
11.4.2 Business Description
11.4.3 Products and Services
11.4.4 Financial Overview
11.4.5 SWOT Analysis
11.5 Parexel International Corp
11.5.1 Key Facts
11.5.2 Business Description
11.5.3 Products and Services
11.5.4 Financial Overview
11.5.5 SWOT Analysis
11.5.6 Key Developments
11.6 Thermo Fisher Scientific Inc.
11.6.1 Key Facts
11.6.2 Business Description
11.6.3 Products and Services
11.6.4 Financial Overview
11.6.5 SWOT Analysis
11.6.6 Key Developments
11.7 Allucent
11.7.1 Key Facts
11.7.2 Business Description
11.7.3 Products and Services
11.7.4 Financial Overview
11.7.5 SWOT Analysis
11.7.6 Key Developments
11.8 PACIFIC BIOLABS
11.8.1 Key Facts
11.8.2 Business Description
11.8.3 Products and Services
11.8.4 Financial Overview
11.8.5 SWOT Analysis
11.8.6 Key Developments
11.9 SGS SA
11.9.1 Key Facts
11.9.2 Business Description
11.9.3 Products and Services
11.9.4 Financial Overview
11.9.5 SWOT Analysis
11.9.6 Key Developments
12. Appendix
12.1 About The Research Team
12.2 Glossary of Terms for Pharmacokinetic Services Market

LIST OF TABLES

Table 1. Europe Pharmacokinetics Services Market Segmentation
Table 2. Germany: Europe Pharmacokinetics Services Market – Revenue and Forecast to 2031 (US$ Million) – by Drug Type
Table 3. Germany: Europe Pharmacokinetics Services Market – Revenue and Forecast to 2031 (US$ Million) – by Service Type
Table 4. Germany: Europe Pharmacokinetics Services Market – Revenue and Forecast to 2031 (US$ Million) – by Therapeutic Application
Table 5. Germany: Europe Pharmacokinetics Services Market – Revenue and Forecast to 2031 (US$ Million) – by End User
Table 6. France: Europe Pharmacokinetics Services Market – Revenue and Forecast to 2031 (US$ Million) – by Drug Type
Table 7. France: Europe Pharmacokinetics Services Market – Revenue and Forecast to 2031 (US$ Million) – by Service Type
Table 8. France: Europe Pharmacokinetics Services Market – Revenue and Forecast to 2031 (US$ Million) – by Therapeutic Application
Table 9. France: Europe Pharmacokinetics Services Market – Revenue and Forecast to 2031 (US$ Million) – by End User
Table 10. United Kingdom: Europe Pharmacokinetics Services Market – Revenue and Forecast to 2031 (US$ Million) – by Drug Type
Table 11. United Kingdom: Europe Pharmacokinetics Services Market – Revenue and Forecast to 2031 (US$ Million) – by Service Type
Table 12. United Kingdom: Europe Pharmacokinetics Services Market – Revenue and Forecast to 2031 (US$ Million) – by Therapeutic Application
Table 13. United Kingdom: Europe Pharmacokinetics Services Market – Revenue and Forecast to 2031 (US$ Million) – by End User
Table 14. Italy: Europe Pharmacokinetics Services Market – Revenue and Forecast to 2031 (US$ Million) – by Drug Type
Table 15. Italy: Europe Pharmacokinetics Services Market – Revenue and Forecast to 2031 (US$ Million) – by Service Type
Table 16. Italy: Europe Pharmacokinetics Services Market – Revenue and Forecast to 2031 (US$ Million) – by Therapeutic Application
Table 17. Italy: Europe Pharmacokinetics Services Market – Revenue and Forecast to 2031 (US$ Million) – by End User
Table 18. Spain: Europe Pharmacokinetics Services Market – Revenue and Forecast to 2031 (US$ Million) – by Drug Type
Table 19. Spain: Europe Pharmacokinetics Services Market – Revenue and Forecast to 2031 (US$ Million) – by Service Type
Table 20. Spain: Europe Pharmacokinetics Services Market – Revenue and Forecast to 2031 (US$ Million) – by Therapeutic Application
Table 21. Spain: Europe Pharmacokinetics Services Market – Revenue and Forecast to 2031 (US$ Million) – by End User
Table 22. Rest of Europe Pharmacokinetics Services Market – Revenue and Forecast to 2031 (US$ Million) – by Drug Type
Table 23. Rest of Europe Pharmacokinetics Services Market – Revenue and Forecast to 2031 (US$ Million) – by Service Type
Table 24. Rest of Europe Pharmacokinetics Services Market – Revenue and Forecast to 2031 (US$ Million) – by Therapeutic Application
Table 25. Rest of Europe Pharmacokinetics Services Market – Revenue and Forecast to 2031 (US$ Million) – by End User
Table 26. Glossary of Terms

LIST OF FIGURES

Figure 1. Europe Pharmacokinetics Services Market Segmentation, by Country
Figure 2. Europe Pharmacokinetics Services Market – Key Market Dynamics
Figure 3. Impact Analysis of Drivers and Restraints
Figure 4. Europe Pharmacokinetics Services Market Revenue (US$ Million), 2021-2031
Figure 5. Europe Pharmacokinetics Services Market Share (%) – by Drug Type (2023 and 2031)
Figure 6. Small Molecule: Europe Pharmacokinetics Services Market – Revenue and Forecast to 2031 (US$ Million)
Figure 7. Large Molecule: Europe Pharmacokinetics Services Market – Revenue and Forecast to 2031 (US$ Million)
Figure 8. Vaccines: Europe Pharmacokinetics Services Market – Revenue and Forecast to 2031 (US$ Million)
Figure 9. Europe Pharmacokinetics Services Market Share (%) – by Service Type (2023 and 2031)
Figure 10. Pre-Clinical ADME and Human Studies: Europe Pharmacokinetics Services Market – Revenue and Forecast to 2031 (US$ Million)
Figure 11. PK/PD Analysis and Reporting: Europe Pharmacokinetics Services Market – Revenue and Forecast to 2031 (US$ Million)
Figure 12. Dosing Simulations: Europe Pharmacokinetics Services Market – Revenue and Forecast to 2031 (US$ Million)
Figure 13. Risk Analysis: Europe Pharmacokinetics Services Market – Revenue and Forecast to 2031 (US$ Million)
Figure 14. Others: Europe Pharmacokinetics Services Market – Revenue and Forecast to 2031 (US$ Million)
Figure 15. Europe Pharmacokinetics Services Market Share (%) – by Therapeutic Application (2023 and 2031)
Figure 16. Oncology: Europe Pharmacokinetics Services Market – Revenue and Forecast to 2031 (US$ Million)
Figure 17. Infectious Diseases: Europe Pharmacokinetics Services Market – Revenue and Forecast to 2031 (US$ Million)
Figure 18. Neurological Disorders: Europe Pharmacokinetics Services Market – Revenue and Forecast to 2031 (US$ Million)
Figure 19. Autoimmune Diseases: Europe Pharmacokinetics Services Market – Revenue and Forecast to 2031 (US$ Million)
Figure 20. Gynecological Disorders: Europe Pharmacokinetics Services Market – Revenue and Forecast to 2031 (US$ Million)
Figure 21. Cardiovascular Diseases: Europe Pharmacokinetics Services Market – Revenue and Forecast to 2031 (US$ Million)
Figure 22. Respiratory Disorders: Europe Pharmacokinetics Services Market – Revenue and Forecast to 2031 (US$ Million)
Figure 23. Others: Europe Pharmacokinetics Services Market – Revenue and Forecast to 2031 (US$ Million)
Figure 24. Europe Pharmacokinetics Services Market Share (%) – by End User (2023 and 2031)
Figure 25. Pharmaceutical and Biotechnology Companies: Europe Pharmacokinetics Services Market – Revenue and Forecast to 2031 (US$ Million)
Figure 26. Contract Research Organization: Europe Pharmacokinetics Services Market – Revenue and Forecast to 2031 (US$ Million)
Figure 27. Others: Europe Pharmacokinetics Services Market – Revenue and Forecast to 2031 (US$ Million)
Figure 28. Europe Pharmacokinetics Services Market – Revenue by Key Countries Revenue 2023 (US$ Million)
Figure 29. Europe Pharmacokinetics Services Market Breakdown, by Key Countries, 2023 and 2031 (%)
Figure 30. Germany: Europe Pharmacokinetics Services Market – Revenue and Forecast to 2031 (US$ Million)
Figure 31. France: Europe Pharmacokinetics Services Market – Revenue and Forecast to 2031 (US$ Million)
Figure 32. United Kingdom: Europe Pharmacokinetics Services Market – Revenue and Forecast to 2031 (US$ Million)
Figure 33. Italy: Europe Pharmacokinetics Services Market – Revenue and Forecast to 2031 (US$ Million)
Figure 34. Spain: Europe Pharmacokinetics Services Market – Revenue and Forecast to 2031 (US$ Million)
Figure 35. Rest of Europe Pharmacokinetics Services Market – Revenue and Forecast to 2031 (US$ Million)